Cure8 research brief
If baseline infliximab clearance and early trough levels predict poor outcomes, clinicians could identify people unlikely to reach remission early in induction and consider dose changes or closer monitoring sooner. That could reduce time spent on ineffective treatment.
Adult patients with ulcerative colitis or Crohn's disease starting infliximab, clinicians who manage biologic dosing and therapeutic drug monitoring, and researchers studying pharmacokinetics and personalized IBD therapy.
This study analyzed a multicenter Phase 4 cohort of adults with Crohn's disease and ulcerative colitis starting standard infliximab induction and used a population pharmacokinetic model to evaluate whether baseline infliximab clearance and early trough levels predict week-30 combined remission.
The authors report that, in ulcerative colitis, higher baseline clearance (>0.28 L/day) and low week-6 trough (≤21.6 mg/L) identified subgroups with very low remission rates, suggesting these metrics could flag patients for early proactive therapeutic drug monitoring during induction. No strong predictors were found for Crohn's disease.
The report frames this as a pragmatic, model-informed, risk-stratified approach and calls for external validation.
What this appears to mean: the paper presents an exposure–response analysis from a registered Phase 4 study and proposes using baseline pharmacokinetic estimates plus early trough measurements to personalize infliximab induction in ulcerative colitis. It does not present practice-changing, validated thresholds yet; the authors recommend external validation.
Practical takeaways: clinicians and researchers may consider baseline clearance and early troughs as candidate markers to study further for early therapeutic drug monitoring during infliximab induction in UC.
Patients on infliximab should not change treatment based on this single study; discussion with the treating team is appropriate if concerned about early drug levels or response.
This is a Phase 4 multicenter study reported in Alimentary Pharmacology & Therapeutics with model-based analyses and predefined sampling; the authors advise external validation before using the specific thresholds in routine care. The article is presented as an abstract-level source in PubMed; it is not a guideline or regulatory change.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Conference analyses describe how subcutaneous infliximab performs after stopping IV treatment and when compared with IV infliximab for ileal/ileocolonic Crohn's — information that could affect treatment decisions for...
Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
